A study due to be published in the Journal of Neurology has raised concerns about dosage implications of switching between generic versions of anti-epileptic drugs (AEDs). Generics are cheaper versions of a branded drug made by a different manufacturer and they may vary from the branded version in terms of their constituents.
What the study led by Dr. Gregory Krauss of Johns Hopkins University Medical School found is that generics also can vary significantly in composition from each other. Whilst this may not be a problem in other medical conditions it is in epilepsy where such differences in dosage and in peak concentrations of AEDs can lead to breakthrough seizures. Previous studies verified the experiences of patients who experienced seizures having been switched from branded to generic versions of drugs. Brainwave has raised this issue at an Oireachtas hearing and has made a submission in respect of concerns about epilepsy and generic prescribing. People with epilepsy in Ireland continue to receive branded version of medications free in the same way as generic versions. Dr. Krauss states that generics have a role in the treatment of epilepsy but advises caution regarding different
versions of generic AEDs. Many people are treated appropriately with generic AEDs - the concerns arise when a switch is made in prescribing or a different version of the generic is substituted by the pharmacy. Brainwave would always advise people with epilepsy to be vigilant for differences in their usual medication when dispensed and to query any change with the pharmacist.